Form 4: Clover Health GC Sells Shares for Tax Obligations

Clover Health's General Counsel, Karen Soares, disposed of 7,459 Class A Common Stock shares at $2.57 each to cover tax obligations related to RSU vesting.

Summary

• Karen Soares, General Counsel & Secretary of Clover Health Investments, Corp. (CLOV), disposed of 7,459 shares of Class A Common Stock.
• The transaction occurred on August 14, 2025, at a price of $2.57 per share.
• The shares were automatically withheld to cover tax obligations upon the vesting of 6.25% of her time-based Restricted Stock Units (RSUs).
• These RSUs were originally granted on February 14, 2022.
• Following this transaction, Karen Soares beneficially owns 1,469,487 shares of Class A Common Stock directly.
• Remaining RSUs will vest quarterly in equal installments of 6.25%, with a final vesting date on February 14, 2026, contingent on her continued service.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax withholding related to RSU vesting, which is a neutral event and does not indicate positive or negative sentiment about the company's performance or outlook.

Positives

• Continued RSU vesting schedule indicates the General Counsel's ongoing employment and commitment to the company through February 2026.

Risks

• Continued RSU vesting is subject to the reporting person's continued service, meaning future vesting could be impacted if employment ceases.

Future Outlook

The remaining Restricted Stock Units (RSUs) are scheduled to vest quarterly in equal installments of 6.25%, with the final vesting occurring on February 14, 2026, contingent on the General Counsel's continued employment.

Industry Context

This is a routine insider transaction (Form 4) related to equity compensation and tax obligations, common across all publicly traded companies that offer Restricted Stock Units (RSUs) to executives. It does not reflect broader industry trends or specific competitive dynamics.

Comparison to Industry Standards

• This transaction is a standard practice for covering tax obligations upon the vesting of equity compensation (RSUs) for executives in publicly traded companies.
• It aligns with typical compensation structures and tax compliance procedures seen across various industries and companies of similar size. There are no specific comparable companies or projects mentioned as this is an individual compensation event.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes. It reflects ongoing executive compensation.

Next Steps

• Remaining Restricted Stock Units (RSUs) will vest quarterly in equal installments of 6.25%.
• Final RSU vesting is scheduled for February 14, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an insider to cover tax obligations upon RSU vesting. Such transactions are common and do not typically reflect a change in the insider's view of the company's prospects or fundamental value. Therefore, it provides no new information that would warrant a change in investment recommendation. The continued vesting schedule indicates the executive's ongoing commitment.

Keywords

Clover Health, CLOV, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Karen Soares, General Counsel, Equity Compensation